{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:07:14Z","timestamp":1789589234986,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","jaapos.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jaapos.2025.104157","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T16:11:39Z","timestamp":1740845499000},"page":"104157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Baseline ophthalmic findings and complications in pediatric patients treated with MEK inhibitors"],"prefix":"10.1016","volume":"29","author":[{"given":"Vikisha","family":"Hazariwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Rossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lasky-Zeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Waanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-6343","authenticated-orcid":false,"given":"Brenda L.","family":"Bohnsack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2025.104157_bib1","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"10.1016\/j.jaapos.2025.104157_bib2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"De Luca","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.jaapos.2025.104157_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: From bench to bedside","volume":"6","author":"Akinleye","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaophthalmol.2016.0090","article-title":"Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer","volume":"134","author":"Weber","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2025.104157_bib5","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2025.104157_bib6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jaapos.2025.104157_bib7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib8","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","article-title":"Ocular safety profile of BRAF and MEK inhibitors: Data from the World Health Organization pharmacovigilance database","volume":"128","author":"Mettler","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2025.104157_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11060-018-2971-9","article-title":"Trametinib for progressive pediatric low-grade gliomas","volume":"140","author":"Kondyli","year":"2018","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib10","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/MPH.0000000000001427","article-title":"Trametinib toxicities in patients with low-grade gliomas and diabetes insipidus: related findings?","volume":"42","author":"Egan","year":"2020","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib11","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1097\/MPH.0000000000002598","article-title":"Use of trametinib in children and young adults with progressive low-grade glioma and glioneuronal tumors","volume":"45","author":"Hanzlik","year":"2023","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib12","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3390\/curroncol31050199","article-title":"Incidence of ophthalmological complications in nf-1 patients treated with MEK inhibitors","volume":"31","author":"Hummel","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib13","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: Differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2025.104157_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s10637-016-0374-3","article-title":"A\u00a0first-in-human phase I study to evaluate the MEK1\/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors","volume":"34","author":"Rosen","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaapos.2025.104157_bib17","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaapos.2025.104157_bib18","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A\u00a0phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib19","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaapos.2025.104157_bib20","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaapos.2025.104157_bib21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","article-title":"Drug-induced uveitis","volume":"29","author":"Moorthy","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jaapos.2025.104157_bib22","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","article-title":"Trametinib: first global approval","volume":"73","author":"Wright","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jaapos.2025.104157_bib23","doi-asserted-by":"crossref","first-page":"e1109","DOI":"10.1634\/theoncologist.2020-0069","article-title":"The use of MEK inhibitors in neurofibromatosis type 1\u2013associated tumors and management of toxicities","volume":"25","author":"Klesse","year":"2020","journal-title":"Oncologist"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853125000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853125000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:52:48Z","timestamp":1744415568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853125000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1091853125000552"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2025.104157","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline ophthalmic findings and complications in pediatric patients treated with MEK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2025.104157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Association for Pediatric Ophthalmology and Strabismus.","name":"copyright","label":"Copyright"}],"article-number":"104157"}}